How much funding has CANbridge raised?

CANbridge has raised $211.0M in total funding, most recently a Series E round.

Who are CANbridge's investors?

CANbridge's investors include Qiming VP, Hong Kong Stock Exchange, Lapam Capital, TF Capital, 3W Fund Management, Casdin Capital.

Where is CANbridge headquartered?

CANbridge is headquartered in Burlington, Massachusetts, China.

What industry is CANbridge in?

CANbridge operates in Life Sciences, Biotech, Healthcare, Rare Diseases.

How many employees does CANbridge have?

CANbridge has 201-500 employees.

CANbridge

formerly CANbridge Pharmaceuticals

Bringing transformative therapies to rare disease patients in China and beyond

Burlington, China · Founded 2012 · $211.0M raised

Life Sciences

Biotech

Healthcare

Rare Diseases

Headquarters: Burlington, Massachusetts
Employees: 201–500
Founded: 2012
Business Model: B2B

Website: canbridgepharma.com
Total Funding: $211.0M
Last Round: $43.0M Series EDec 2020
Rounds: 6

About

CANbridge Pharmaceuticals (HKEX: 1228) is a global biopharmaceutical company with a foundation in China, committed to the research, development, and commercialization of rare disease therapeutics. The company has a differentiated drug portfolio with 3 approved drugs and a pipeline of 7 clinical assets, focusing on prevalent rare disease indications including mucopolysaccharidosis, Gaucher disease, and other rare genetic disorders. CANbridge operates a Next-Generation Innovation and Process Development Facility developing novel gene therapies, and partners globally with leading biotech and pharma companies to bring treatments to patients in China and worldwide.

Summary

CANbridge is a Life Sciences company based in Burlington, China, founded in 2012. It has raised $211.0M in total across 6 rounds, most recently a $43.0M Series E round in Dec 2020. Investors include Qiming VP, Hong Kong Stock Exchange and Lapam Capital.